UBS AM’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-24,360
| Closed | -$564K | – | 2731 |
|
|
2023
Q2 | $564K | Hold |
24,360
| – | – | ﹤0.01% | 2276 |
|
|
2023
Q1 | $564K | Sell |
24,360
-9,258
| -28% | -$221K | ﹤0.01% | 2276 |
|
|
2022
Q4 | $881K | Buy |
33,618
+5,076
| +18% | +$112K | ﹤0.01% | 1908 |
|
|
2022
Q3 | $561K | Buy |
28,542
+13,433
| +89% | +$269K | ﹤0.01% | 2294 |
|
|
2022
Q2 | $264K | Buy |
+15,109
| New | +$237K | ﹤0.01% | 2507 |
|
|
2019
Q4 | – | Sell |
-11,239
| Closed | -$59.6K | – | 2901 |
|
|
2019
Q3 | $59.6K | Buy |
11,239
+192
| +2% | +$1.27K | ﹤0.01% | 2705 |
|
|
2019
Q2 | $85.1K | Buy |
11,047
+5,707
| +107% | +$86.9K | ﹤0.01% | 2662 |
|
|
2019
Q1 | $106K | Hold |
5,340
| – | – | ﹤0.01% | 2561 |
|
|
2018
Q4 | $70.5K | Hold |
5,340
| – | – | ﹤0.01% | 2545 |
|
|
2018
Q3 | $196K | Hold |
5,340
| – | – | ﹤0.01% | 2453 |
|
|
2018
Q2 | $187K | Hold |
5,340
| – | – | ﹤0.01% | 2492 |
|
|
2018
Q1 | $248K | Buy |
+5,340
| New | +$195K | ﹤0.01% | 2287 |
|
|
2016
Q4 | – | Sell |
-2,660
| Closed | -$165K | – | 2707 |
|
|
2016
Q3 | $165K | Hold |
2,660
| – | – | ﹤0.01% | 2506 |
|
|
2016
Q2 | $150K | Hold |
2,660
| – | – | ﹤0.01% | 2526 |
|
|
2016
Q1 | $170K | Sell |
2,660
-36,666
| -93% | -$2.97M | ﹤0.01% | 2473 |
|
|
2015
Q4 | $5.53M | Buy |
+39,326
| New | +$5.34M | 0.01% | 1031 |
|
|
2015
Q3 | – | Sell |
-16,802
| Closed | -$2.55M | – | 2702 |
|
|
2015
Q2 | $2.55M | Buy |
+16,802
| New | +$2.77M | ﹤0.01% | 1295 |
|
UBS AM's KDNY Position: Q3 2023 in Review
UBS AM sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 24,360 shares — an estimated $564K sold.
UBS AM first reported a position in KDNY in Q2 2015 and held it in 17 quarters. The position peaked at $5.53M in Q4 2015. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- UBS AM reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- UBS AM sold 24,360 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $564K.
- UBS AM first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 17 quarters.
- UBS AM's Chinook Therapeutics, Inc. Common Stock position peaked at $5.53M in Q4 2015.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.